472 related articles for article (PubMed ID: 27984538)
1. Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.
Jeong JH; Kong EJ; Jeong SY; Lee SW; Cho IH; Ah Chun K; Lee J; Ahn BC
Nucl Med Commun; 2017 Mar; 38(3):228-233. PubMed ID: 27984538
[TBL] [Abstract][Full Text] [Related]
2. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
3. Low- and high-dose radioiodine therapy for low-/intermediate-risk differentiated thyroid cancer: a preliminary clinical trial.
Qu Y; Huang R; Li L
Ann Nucl Med; 2017 Jan; 31(1):71-83. PubMed ID: 27757803
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of low radioiodine activity versus intermediate-high activity in the ablation of low-risk differentiated thyroid cancer.
Albano D; Bonacina M; Durmo R; Bertagna F; Giubbini R
Endocrine; 2020 Apr; 68(1):124-131. PubMed ID: 31784881
[TBL] [Abstract][Full Text] [Related]
5. Delayed initial radioiodine therapy related to incomplete response in low- to intermediate-risk differentiated thyroid cancer.
Li H; Zhang YQ; Wang C; Zhang X; Li X; Lin YS
Clin Endocrinol (Oxf); 2018 Apr; 88(4):601-606. PubMed ID: 29338092
[TBL] [Abstract][Full Text] [Related]
6. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension.
Han JM; Kim WG; Kim TY; Jeon MJ; Ryu JS; Song DE; Hong SJ; Shong YK; Kim WB
Thyroid; 2014 May; 24(5):820-5. PubMed ID: 24328997
[TBL] [Abstract][Full Text] [Related]
7. Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial.
Dong P; Qu Y; Yang L; Xiao L; Huang R; Li L
Clin Endocrinol (Oxf); 2021 Nov; 95(5):782-789. PubMed ID: 34368999
[TBL] [Abstract][Full Text] [Related]
8. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients.
Castagna MG; Cevenini G; Theodoropoulou A; Maino F; Memmo S; Claudia C; Belardini V; Brianzoni E; Pacini F
Eur J Endocrinol; 2013 Jul; 169(1):23-9. PubMed ID: 23594687
[TBL] [Abstract][Full Text] [Related]
9. The Prospective Implementation of the 2015 ATA Guidelines and Modified ATA Recurrence Risk Stratification System for Treatment of Differentiated Thyroid Cancer in a Canadian Tertiary Care Referral Setting.
Wu J; Hu XY; Ghaznavi S; Kinnear S; Symonds CJ; Grundy P; Parkins VM; Sharma P; Lamb D; Khalil M; Hyrcza M; Chandarana SP; Pasieka JL; Harvey A; Warshawski J; Hart R; Deutschman M; Randall DR; Paschke R
Thyroid; 2022 Dec; 32(12):1509-1518. PubMed ID: 36226405
[No Abstract] [Full Text] [Related]
10. Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer.
Yu F; Li X; Ji Y; Tan J; Zhang G; Wang P; He Y; Wang R
Front Endocrinol (Lausanne); 2021; 12():743310. PubMed ID: 34858329
[TBL] [Abstract][Full Text] [Related]
11. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
Scheffel RS; Zanella AB; Dora JM; Maia AL
Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
[TBL] [Abstract][Full Text] [Related]
12. Low activity versus high activity: noninferior response to radioiodine therapy in differentiated patients with extrathyroid extension.
Wang C; Zhao T; Li H; Gao W; Lin Y
Nucl Med Commun; 2017 May; 38(5):366-371. PubMed ID: 28362717
[TBL] [Abstract][Full Text] [Related]
13. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.
Khang AR; Cho SW; Choi HS; Ahn HY; Yoo WS; Kim KW; Kang KW; Yi KH; Park DJ; Lee DS; Chung JK; Cho BY; Park YJ
Clin Endocrinol (Oxf); 2015 Jul; 83(1):117-23. PubMed ID: 25115234
[TBL] [Abstract][Full Text] [Related]
14. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
[TBL] [Abstract][Full Text] [Related]
15. Intermediate-risk differentiated thyroid carcinoma patients who were surgically ablated do not need adjuvant radioiodine therapy: long-term outcome study.
Ballal S; Soundararajan R; Garg A; Chopra S; Bal C
Clin Endocrinol (Oxf); 2016 Mar; 84(3):408-16. PubMed ID: 25823589
[TBL] [Abstract][Full Text] [Related]
16. Second Radioiodine Treatment: Limited Benefit for Differentiated Thyroid Cancer With Locoregional Persistent Disease.
Hirsch D; Gorshtein A; Robenshtok E; Masri-Iraqi H; Akirov A; Duskin Bitan H; Shimon I; Benbassat C
J Clin Endocrinol Metab; 2018 Feb; 103(2):469-476. PubMed ID: 29126111
[TBL] [Abstract][Full Text] [Related]
17. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
18. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.
Park S; Kim WG; Song E; Oh HS; Kim M; Kwon H; Jeon MJ; Kim TY; Shong YK; Kim WB
Thyroid; 2017 Apr; 27(4):524-530. PubMed ID: 27869547
[TBL] [Abstract][Full Text] [Related]
19. Low-risk papillary thyroid carcinoma patients who underwent near-total thyroidectomy without prophylactic central compartment lymph node dissection and were ablated with low-dose 50mCi RAI had excellent 10-year prognosis.
Michalaki M; Bountouris P; Roupas ND; Theodoropoulou A; Agalianou N; Alexandrides T; Markou K
Hormones (Athens); 2016 Oct; 15(4):511-517. PubMed ID: 28222412
[TBL] [Abstract][Full Text] [Related]
20. Recurrent disease in juvenile differentiated thyroid carcinoma: prognostic factors, treatments, and outcomes.
Mihailovic J; Nikoletic K; Srbovan D
J Nucl Med; 2014 May; 55(5):710-7. PubMed ID: 24722527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
